Table 3.

Recommendations for routine* monitoring of BRAF/MEK combination therapy

Test	Therapy start	Monthly control	Quarterly control
Blood count
Differential blood count	x	x
Clinical chemistry
Electrolytes (Na, K, Ca, Mg)	x	x
Creatinine	x	x
CPK	x	x
Troponin	x	(x)†	x
NT-proBNP	x	(x)†	x
Liver transaminases (AST, ALT, γ-GT)	x	x
Bilirubin	x	x
Examinations (non-laboratory tests)
Skin inspection	x	x‡	x
Visual acuity control §	x	(x)¶
Ocular OCT		(x)¶
Blood pressure	x	x
ECG	x	x‡	x
Echocardiography	x		(x)†

*In patients/situations without clinical particularities.

†In case of clinically abnormal signs (eg, heart, chest) or increasing CPK.

‡In months 1 and 2.

§Visual acuity (at therapy start) to be checked/noted (ie, in patient history).

¶in case of patient-reported visual disturbances.

γ-GT, gamma-glutamyl transferase;ALT, alanine transaminase;AST, aspartate transaminase;CPK, creatine phosphokinase;LDH, lactate dehydrogenase;NT-proBNP, N-terminal prohormone of brain natriuretic peptide;OCT, optical coherence tomography; x, test recommended; (x), test optional.